Breaks Categories: News

FridayJun 19, 2020 12:19 pm

CannabisNewsBreaks – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) Partners with Medipharm Labs to Leverage GMP Production Capabilities, Accelerate Australian Market Presence

VIVO Cannabis (TSX: VIVO) (OTCQX: VVCIF) today announced that its subsidiary, Beacon Medical Australia Pty. Ltd. ("Beacon Medical Australia"), entered into an agreement with MediPharm Labs Australia Pty. Ltd. ("MediPharm Labs Australia"), a subsidiary of MediPharm Labs Corp. (TSX: LABS) ("MediPharm Labs"). Under the agreement, MediPharm Labs Australia will supply pharmaceutical-quality (GMP certified), formulated cannabis oil products to Beacon Medical Australia to sell into the Australian market. "VIVO's international efforts remain focused on the emerging Australian and German markets and we continue to seek out partnerships with organizations that have proven track records," Barry Fishman, CEO of VIVO, said in…

Continue Reading

FridayJun 19, 2020 10:20 am

CannabisNewsBreaks – Champignon Brands Inc.’s (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Dr. McIntyre / CRTCE Published in Two Peer Reviewed Study Journals

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (“MDD”) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company today announced that its Chief Executive Officer, Dr. Roger McIntyre, and the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) have been recently published in two peer reviewed study journals (the “Peer Reviewed Studies”) focusing on ketamine’s safety, tolerability and effectiveness. “The publications of data as it relates…

Continue Reading

ThursdayJun 18, 2020 10:28 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applies for NIH Grant to Support COVID-19 Therapy Studies, Receives Expanded Health Canada License

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled "In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement." According to the update, the grant application is for funding to support Lexaria's second round of planned studies related to COVID-19 treatment possibilities. Additionally, the Company also reported that its subsidiary Lexaria CanPharm ULC has received a new license from Health Canada, issued in accordance with the…

Continue Reading

WednesdayJun 17, 2020 11:27 am

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) Announces Further Acceleration of Path to Commercialization, Expands Portfolio

Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), a Canadian biotechnology company creating high purity, plant-derived compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries, today announced further acceleration of its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. "Willow's scientific and operational success to date has solidified the use of yeast fermentation as a production platform," Willow's CEO Trevor Peters stated in the news release. "Our scientific discoveries over the past 14 months have contributed to the development of not one, but five different cannabinoids and our pilot…

Continue Reading

MondayJun 15, 2020 12:12 pm

CannabisNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Expands Agreement with Stillwater Brands to Launch RIPPLE Suite of Products

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium, certified-organic cannabis, today announced the expansion of its exclusive licensing agreement with Colorado-based Stillwater Brands, under which it will be rolling out the powerful RIPPLE suite of products in Canada, including RIPPLE Gummies and RIPPLE QuickSticks. According to the update, TGOD leveraged Stillwater's proprietary technology to launch its first Cannabis 2.0 product at the end of March – TGOD Infuser 10mg THC – which quickly became one of the top selling SKUs within the beverage category across the country. Given the first product’s success, TGOD has…

Continue Reading

MondayJun 15, 2020 10:52 am

CannabisNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Announces Strategic Board Appointment of Canopy Growth CFO Mike Lee

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced appointment of Canopy Growth Corporation ("Canopy Growth") (TSX: WEED), (NYSE: CGC) Chief Financial Officer Mike Lee to its Board of Directors (the "Board"). According to the update, the Company expects that Lee's experience at Canopy Growth, Constellation Brands, Inc. and other leading consumer packaged goods and beverage companies will help strengthen its strategic execution as it continues to focus on developing a leading global cannabis portfolio. "Mike's addition to our Board is another sign of our strong and growing relationship with Canopy Growth and Constellation…

Continue Reading

MondayJun 15, 2020 10:08 am

CannabisNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Announces Leadership Change

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) on Friday announced that Brian Logan is stepping down as chief financial officer, effective July 15, 2020.  Logan has served as GGB’s CFO since January 2019. “On behalf of GGB, I want to thank Brian for his many and significant contributions during his tenure as CFO of the Company,” Randy Whitaker, GGB’s interim CEO, said in the news release. “I wish him the best of luck in his future endeavors.” To view the full press release, visit http://cnw.fm/1s2WU About Green Growth Brands Inc. Green Growth Brands creates remarkable experiences in cannabis. The company's…

Continue Reading

MondayJun 15, 2020 9:41 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Provides Corporate Update

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Friday provided a corporate update. Since commencing trading on March 2, 2020, the Company has expanded its initiatives and rapidly executed on such initiatives to position it as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder (“PTSD”), and substance-use disorders (“SUD”) via the clinical delivery of ketamine and ketamine-derivatives. In the update, the Company shared its corporate advancements and achievements over the last quarter, which target key segments in…

Continue Reading

TuesdayJun 09, 2020 10:28 am

CannabisNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Announces Retirement of CFO, Names Successor

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp branded products company in the U.S., today announced that its Chief Financial Officer, Jon Paul, will be retiring at the end of this month. According to the update, current Vice President of Finance, Nate Pearson, has been identified as his successor, while Paul, following his retirement, will continue in an advisory role to ensure a smooth transition. “Jon has played an integral role in our organization since the day he joined,” Jake Heimark, co-founder and CEO of Plus Products, stated in the news release. “The financial and regulatory environments in…

Continue Reading

MondayJun 08, 2020 11:11 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Engages Toronto-based Dalriada to Advance NCE IP Portfolio

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced its selection of Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. According to the update, Dalriada, a leading contract research organization (“CRO”) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms. “It is with…

Continue Reading